Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AD/PD 2024 | Prognostic value of plasma biomarkers GFAP and pTau181 for all-cause and Alzheimer’s dementia

Madison Honey, PhD candidate, Amsterdam University Medical Centre, Amsterdam, Netherlands, presents the findings of a study measuring the prognostic value of plasma NfL, GFAP, p-tau181, and Aβ42/Aβ40 in a cohort of patients with mild cognitive impairment (MCI). Plasma GFAP showed very good prognostic value, with a significant capacity to predict which patients would convert from MCI to all-cause dementia. Both plasma GFAP and p-tau181 showed good prognostic capacity for predicting Alzheimer’s disease conversion, specifically. Combining the GFAP and p-tau181 biomarkers in a model utilizing patient age, sex, and mini-mental state examination (MMSE) score presented the greatest value – the team were able to develop individualized risk estimates for MCI conversion to AD. This interview took place at the AP/PD™ 2024 congress in Lisbon, Portugal.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.